Dolutegravir/rilpivirine (DTG/RPV), sold under the brand name Juluca, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It contains the medicines dolutegravir and rilpivirine. It is taken orally (by mouth).
The most common adverse reactions (of all severity grades) are diarrhea and headache.
Dolutegravir/rilpivirine was approved for use in the United States in November 2017, and for use in the European Union in May 2018. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. __TOC__
Medical uses Dolutegravir/rilpivirine is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.
References